DAONIL TABLET 5MG

País: Malàisia

Idioma: anglès

Font: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ingredients actius:

GLIBENCLAMIDE

Disponible des:

SANOFI-AVENTIS (MALAYSIA) SDN. BHD.

Designació comuna internacional (DCI):

GLIBENCLAMIDE

Unidades en paquete:

100Tablet Tablets; 100 Tablet Tablets

Fabricat per:

PT AVENTIS PHARMA

Informació per a l'usuari

DAONIL
®
Glibenclamide
_Consumer Medication Information Leaflet (RiMUP)_
5mg Tablet
_ _
WHAT IS IN THIS LEAFLET
1. What Daonil is used for
2. How Daonil works
3. Before you use Daonil
4. How to use Daonil
5. While you are using it
6. Side effects
7. Storage and Disposal of Daonil
8. Product Description
9.
Manufacturer
and
Product
Registration Holder
10.Date of revision
WHAT DAONIL IS USED FOR
Daonil
is
used
to
control
blood
glucose levels in patients with type 2
diabetes
mellitus.
This
type
of
diabetes
is
also
known
as
non-
insulin-dependent
diabetes
(NIDDM)
or
maturity
onset
diabetes.
Daonil is used in conjunction with
diet control and exercise to control
blood sugar.
Daonil
can
be
used
alone,
or
in
combination
with
insulin
or
other
anti-diabetes medicines.
HOW DAONIL WORKS
Daonil lowers high blood glucose by
increasing
the
amount
of
insulin
released by your pancreas.
Daonil
belongs
to
a
group
of
medicines called sulphonylureas.
If your blood glucose is not properly
controlled,
you
may
experience
hypoglycaemia (low blood glucose)
or
hyperglycaemia
(high
blood
glucose).
High
blood
glucose
can
lead to serious problems with your
heart, eyes, circulation or kidneys.
Low
blood
glucose
can
occur
suddenly. Signs may include:

weakness, trembling, shaking

sweating

light
headedness,
dizziness,
headache
or
lack
of
concentration

tearfulness, crying or depression

irritability

hunger

numbness
around
the
lips
and
tongue

restlessness or disturbed sleep
If not treated promptly, these may
progress to:

loss of co-ordination

slurred speech

confusion

loss of consciousness or seizures
High blood glucose usually occurs
more slowly than low blood glucose.
Signs
of
high
blood
glucose
may
include:

lethargy or tiredness

headache

severe thirst

passing large amounts of urine
and more often

blurred vision

dry mouth or dry skin
This medicine is available only with
a doctor’s prescription.
Daonil
is not addictive.
BEFORE YOU USE DAONIL
_WHEN YOU MUST NOT TAKE IT _
DO NO

Fitxa tècnica

DAONIL
Glibenclamide
This package insert is continually updated: please read carefully before using a new pack. In case
of any question, please contact your physician or pharmacist.
PRODUCT DESCRIPTION
Tablets, 5 mg (white, biplane oblong tablet with a score-line on both sides. LDI is engraved each
side of the score-line and inverted. The other side is plain).
COMPOSITION
Each tablet contains, as active ingredient, 5mg glibenclamide. Excipients are lactose, maize
starch, talc, colloidal silica and magnesium stearate.
PHARMACOLOGY
Site and Mode of Action
DAONIL appears to lower the blood glucose acutely in healthy individuals and patients with type 2
diabetes by stimulating the release of insulin from the pancreas, an effect dependent upon
functioning beta cells. It acts in concert with glucose (improved sensitivity of beta cells to
physiological glucose stimulus) and leads to an insulin secretion in the rhythm of meals. Other
mechanisms of the hypoglycaemic action associated with short term therapy appear to include
reduction of basal hepatic glucose production and enhancement of peripheral insulin action at
post-receptor (probably intracellular) sites.
With chronic administration of DAONIL
in patients with type 2 diabetes, the improvement in
glucose tolerance persists despite a gradual decline in glucose- or meal-stimulated secretion of
insulin towards pretreatment levels. Extrapancreatic effects appear to contribute substantially to
the hypoglycaemic action of the drug during long term administration. The effects appear to include
enhanced peripheral sensitivity to insulin and reduction of basal hepatic glucose production. There
is evidence that glibenclamide enhances the peripheral action of insulin at post-receptor (probably
intracellular) sites and increases insulin binding and/or the number of insulin receptors.
Glibenclamide also exerts a direct inhibitory effect on glucagon-producing alpha cells of the
pancreas and increases the release of somatostatin. However, these two pancreatic extra-beta cell
act